Health Care · Services-General Medical & Surgical Hospitals, NEC

ARDT Ardent Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 175665550 filings
Russell 2000

ARDT at a glance

Ardent Health, Inc. (ARDT, SEC CIK 1756655) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Ardent Health, Inc. (ARDT) shares worth $220.5 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by DeMichiei Robert on June 5, 2026 of 11,260 shares at $8.73 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.3B
+6.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$220.5M · −1 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $1,624.9M, up $48.1M or 3.1% YoY, driven by adjusted admissions growth of 2.9%
  • Net income attributable to Ardent $44.5M, margin 2.7% vs negative 1.5% YoY
  • Medicaid supplemental payments $156.9M vs $186.5M YoY, the primary revenue headwind
  • Cash $766.2M and available liquidity $1,009.8M at September 30, 2026
  • Operating cash flow $258.4M vs $247.1M YoY, with $115.6M capital expenditures and $24.0M share repurchases year-to-date

Risk Factors

  • No material changes to previously disclosed risk factors in the Annual Report
  • Regulatory, legal, and compliance risks remain those identified in the Annual Report
  • Operational and competitive risks remain those identified in the Annual Report
  • Liquidity, debt, currency, and concentration risks remain those identified in the Annual Report

AI summary of the ARDT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 8.01: Other Events

  • Selling stockholders sold 8,000,000 shares at $14.50, increasing public float without diluting Ardent Health
  • Ardent received no offering proceeds, limiting direct balance-sheet benefit from the transaction
Filed Nov 12, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Ardent Health agreement to acquire Boone Health, a Columbia, Missouri not-for-profit health system
  • $47 million cash purchase price, creating a near-term cash deployment and acquisition funding consideration

Item EX-99.1: Item EX-99.1

  • $47 million cash acquisition of Boone Health, including 392-bed hospital, 19 care sites and related real estate
  • Boone Health adds approximately $480 million annual revenue and a 26-county Missouri service area
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Ardent Health reported third-quarter fiscal 2026 results for the period ended September 30, 2026
  • Press release issued November 4, 2026, with detailed financial results in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.625B, up 3.1% YoY, while adjusted admissions grew 2.9%, signaling improving utilization
  • Net income attributable to Ardent $45M, or $0.31 diluted EPS, versus a $23M loss, or $(0.17), last year

AI summaries of ARDT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ARDT

Don't miss the next ARDT filing

  • Alerts as it files. A push when ARDT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ARDT, by share count.
  • Ask anything. An AI agent that reads every ARDT filing and answers with sources.

ARDT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
LUMSDAINE ALFREDFSep 25, 2026$10.54
Petrovich Stephen C.FSep 25, 2026$10.54
Byers David RaynorFSep 25, 2026$10.54
Caspers DaveAJul 1, 2026-
DeMichiei RobertBuyJun 5, 2026$8.73
LUMSDAINE ALFREDBuyJun 5, 2026$8.81
Havdala EllenAApr 1, 2026-
LUMSDAINE ALFREDAApr 1, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$5.4B$6.0B$6.3B
Net Income$53.9M$210.3M$135.8M
Net Margin1.0%3.5%2.1%
Balance Sheet
Total Assets$4.7B$5.0B$5.3B
Equity$670.9M$1.1B$1.3B
ROE8.0%18.6%10.5%
Per Share
EPS$0.43$1.58$0.96
Cash Flow
Operating CF$221.7M$315.0M$470.5M

Source: XBRL data in Ardent Health, Inc. (ARDT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ARDT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ARDT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$220.5M
Q2 202628$191.2M
Q1 202625$154.3M
Q4 202523$161.9M
Q3 202523$248.8M
Q2 202524$120.5M
Q1 202519$90.8M
Q4 202414$231.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ARDT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
8-KNov 12, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 23, 2026Analysis-
4Sep 29, 2026--
4Sep 29, 2026--
4Sep 29, 2026--
8-KSep 4, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 2, 2026--
8-KJun 30, 2026Analysis-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 2, 2026Analysis
8-KMay 26, 2026Analysis
10-QMay 6, 2026Analysis
8-KMay 5, 2026Analysis-
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--
4Apr 2, 2026--

Related Health Care companies

All Health Care →

ARDT SEC filings: frequently asked questions

Which institutions hold ARDT stock?

As of September 30, 2026, the largest Ardent Health, Inc. (ARDT) holders among the 13F filers tracked by SignalX were Ventas ($96.6 million), BlackRock ($23.4 million), Ameriprise Financial ($22.4 million), AQR Capital Management ($15.6 million), Vanguard Capital Management LLC ($12.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ARDT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Ardent Health, Inc. (ARDT) reported revenue of $6.3 billion (up 6.0% from FY2024) and net income of $135.8 million. Diluted EPS was $0.96. The figures come from the XBRL data in the 10-K.

What did ARDT report in its latest 8-K?

Ardent Health, Inc. (ARDT) filed an 8-K on November 19, 2026 reporting Item 8.01 (Other Events). Selling stockholders sold 8,000,000 shares at $14.50, increasing public float without diluting Ardent Health.

What are the latest ARDT SEC filings?

Ardent Health, Inc. (ARDT) filed its latest 10-K annual report on March 16, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on September 29, 2026.

What is ARDT's SEC CIK number?

Ardent Health, Inc. (ARDT)'s SEC Central Index Key (CIK) is 1756655. EDGAR lists every ARDT filing under that number.

Ask anything about ARDT

The research agent reads ARDT's filings, financials, insider trades and 13F holders, then answers with sources.